Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery

To evaluate the safety and efficacy of an anterior chamber intracameral dexamethasone drug-delivery suspension (IBI-10090; DEXYCU; Icon Bioscience Inc., Newark, CA) that provides medication for up to 21 days with a single application in treating postoperative inflammation in patients undergoing cataract surgery.

Source: Ophthalmology - February 3, 2018 Category: Opthalmology Authors: Eric Donnenfeld, Edward Holland Source Type: research